Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Novartis | Ruxolitinib | Jakavi |  | 2012-08-23 | $1,828 M | Q2/22-Q2/25 |
Bristol Myers Squibb | Fedratinib | Inrebic |  | 2021-02-08 | $110 M | Y2023 |
Endo | Sodium phenylbutyrate | Phenylbutyrate |  | 2016-06-15 |  |  |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|